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Recent human studies found that the mRNA expression level of aryl-hydrocarbon receptor nuclear
translocator 2 (ARNT2) was positively associated with the prognosis of breast cancer. In this study,
we used small interfering RNA techniques to knockdown ARNT2 expression in MCF7 human breast
cancer cells, and found that an almost 40% downregulation of ARNT2 mRNA expression increased
the expression of sensitive to apoptosis gene (3.36-fold), and decreased the expression of von Hippel-
Lindau (0.27-fold) and matrix metalloproteinase-1 (0.35-fold). The metabolite analysis revealed the
contents of glucose, glycine, betaine, phosphocholine, pyruvate and lactate involved in the hypoxia-
inducible factor (HIF)-1-dependent glycolytic pathway were signiﬁcantly lower in cells treated with
siARNT2. Our results suggested that ARNT2 might play an important role in the modulation of HIF-1-
regulated signaling andmetabolism.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Aryl-hydrocarbon receptor nuclear translocator 2 (ARNT2) is a
member of the basic helix-loop-helix Per-ARNT-SIM family of tran-
scription factors [1] and acts as a common obligate partner for sev-
eral other members of the family, including aryl hydrocarbon
receptor (AHR) and hypoxia-inducible factor (HIF)-1a [2,3].
Although many of the functions of ARNT2 remain unknown, it is
believed that ARNT2 plays important roles in tumor angiogenesis
by forming functional HIF complexes [4]. A recent study showed
that ARNT2 mRNA expression levels are positively correlated withchemical Societies. Published by E
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k.the prognosis of breast cancer, and that the presence of ARNT2 was
signiﬁcantly associated with smaller tumor sizes (P = 0.006),
relapse-free survival (P = 0.027), and overall survival (P = 0.002)
5 years after breast cancer diagnosis [5]. These perspective ﬁndings
indicate a possible role of ARNT2 in cancer development, treatment
and outcome; however, much of this has yet to be elucidated.
Metabolites are regarded as the end products of cellular regula-
tory processes, and their levels can be considered as the ultimate
response of biological systems to genetic or environmental
changes [6]. The metabolism of a solid tumor is signiﬁcantly differ-
ent from that of the surrounding normal tissue, with cancer cells
shifting glucose metabolism from oxidative to glycolytic pathways
[7]. This process is known as the Warburg effect, at the heart of
which is the HIF-dependent (and in particular, HIF-1-dependent)
transcriptional regulation of virtually all of the genes in the glyco-
lytic pathway, including glucose transporters, glycolytic enzymes,
and various proteins involved in lactate production and pyruvate
metabolism [8]. Nuclear magnetic resonance (NMR)-based meta-
bolic proﬁling and metabolomics, combined with multivariate sta-
tistical analysis, have been widely applied in various areas of
research, including drug toxicology, biomarker discovery, func-
tional genomics, and molecular pathology [9–13]. Compared to
other analytical techniques, such as gas chromatography–masslsevier B.V. All rights reserved.
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has the advantage of a fully quantitative analysis (with minimal
sample preparation) to achieve a quick, direct and comprehensive
observation [14].
In this study, NMR-based metabolomics was employed to inves-
tigate whether dysregulated ARNT2 mRNA expression could affect
HIF-1-regulated metabolism in MCF7 human breast cancer cells. To
assess the potential function of ARNT2 in breast cancer, we utilized
small interfering RNA (siRNA) to knockdown ARNT2 mRNA expres-
sion levels in MCF7 cells, and then investigated its effect on the
HIF-1 regulated signaling and metabolism.
2. Materials and methods
2.1. Cell culture
MCF7 cells were obtained from the Cell Engineering Division of
RIKEN BioResource Center (Tsukuba, Ibaraki, Japan). Cells were
maintained in RPMI 1640 medium (Wako, Osaka, Japan) containing
10% fetal bovine serum (FBS) (Mediatech, Herndon, VA) and grown
at 37 C in a 5% CO2 humidiﬁed incubator. For growth under ste-
roid-free conditions, the cells were seeded in phenol red-free
DMEM (MP Biomedicals, Solon, OH) containing 10% charcoal/dex-
tran-treated FBS (Hyclone, Logan, UT). All culture media contained
100 U/ml penicillin/streptomycin and 2 mmol/l L-glutamine
(Mediatech).
2.2. RNA interference
siRNA targeting human ARNT2 (50-CCGAUGGAAUCAUCA-
CAUUUU-30) and a scrambled sequence were designed and pur-
chased from Genolution Pharmaceuticals Inc. (Seoul, South
Korea). MCF7 cells were plated in 96-well plates (1  104 cells/
well) for cell viability analysis, 24-well plates (5  104 cells/well)
for RNA isolation, and 100 mm dishes (1  106 cells/dish) for
metabolite analysis in phenol red-free media 1 day prior to trans-
fection. Cells were then transfected with 10 nM or 100 nM siARNT2
and the scrambled siRNA as a negative control using G-Fectin, as
per the manufacturer’s instructions (Genolution Pharmaceuticals).
The transfected cells were then incubated at 37 C for 72 h and cul-
tured in phenol red-free media without siARNT2 for another 48 h
before analysis.
2.3. Quantitative real-time reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA was isolated from cell cultures using an RNeasy Kit
(Qiagen, Valencia, CA), and their amounts, purity and integrity
were evaluated using a UV spectrophotometer and an Agilent Bio-
analyzer 2100 (Agilent Technologies, Palo Alto, CA). cDNA was then
synthesized using a High Capacity RNA-to-cDNA Kit (Applied Bio-
systems, Foster City, CA) and ampliﬁed in triplicate using TaqMan
Gene Expression Master Mix (Applied Biosystems) as previously
described [15]. TaqMan Gene Expression Assays (Applied Biosys-
tems) used in this study were Hs00208298_m1 for ARNT2,
Hs00231048_m1 for ARNT, and Hs99999903_m1 for beta-actin.
The gene expression was normalized to beta-actin expression
and set to 1.0 for control cells treated with scramble siRNA.
2.4. Cell viability assay
Cells were washed twice with cold phosphate-buffered saline
(PBS, Gibco, Grand Island, NY) and then ﬁxed in 4% neutralized
paraformaldehyde solution for 30 min. Nuclear counter-staining
was detected with Hoechst 33258 (Wako Pure Chemical Industries,
Osaka, Japan) and high-content cellular ﬂuorescence images wereacquired using an automatic ﬂuorescence microscope (IN Cell Ana-
lyzer 1000; GE Healthcare, Buckinghamshire, UK).
2.5. Human HIF-regulated cDNA plate array
A human HIF-regulated cDNA plate array was used to deter-
mine the effect of downregulated ARNT2 mRNA expression on
HIF-1 signaling (AP-0111, Signosis Inc., Sunnyvale, CA), according
to the manufacturer’s instructions. Brieﬂy, total RNA (2 lg) was
ﬁrst reverse transcribed into cDNA in the presence of biotin-dUTP.
Target genes were then speciﬁcally captured to individual wells on
the plate through a pre-coated gene-speciﬁc oligonucleotide. The
captured cDNAs were then detected with streptavidin-horseradish
peroxidase (HRP) by the addition of a HRP chemiluminescent sub-
strate. The concentration of cDNA was directly proportional to the
chemiluminescent intensity of the test sample. The luciferase
activity was measured using an AB-2100 luminometer (Atto,
Tokyo, Japan). Luciferase induction was normalized to beta-actin
and set to 1.0 for control cells treated with scramble siRNA.
2.6. NMR sample preparation
For metabolite analysis, MCF7 cells were harvested, as previ-
ously reported [16]. Brieﬂy, cells (approximately 1  107 cells)
were pelleted and washed twice with cold PBS to remove any
residual medium. Excess PBS was removed via two rounds of cen-
trifugation at maximum speed. Cell pellets were then stored at
80 C for subsequent extraction. Aqueous soluble metabolites
were then extracted using a chloroform/methanol/water extrac-
tion method, as previously described [13].
2.7. NMR analysis
The one-dimensional (1D) 1H NMR spectra were measured at
500 MHz on a Varian Unity INOVA-500 spectrometer. The H2O sig-
nal was suppressed by the pre-saturation method. The acquisition
parameters were as follows: number of data points, 64 k; spectral
width, 8000 Hz; acquisition time, 4.000 s; delay time, 2.0 s; and
number of scans, 256. Detailed methods have been described pre-
viously [17].
2.8. Processing of spectra and data reduction
All NMR spectra were processed with the program MestReNova
(Version 5.3.0, MestReC, Santiago de Compostela, Spain), reduced
into 0.04 ppm spectral buckets, aligned using the Correlation Opti-
mized Warping method, and then normalized.
2.9. Identiﬁcation of metabolites
Metabolites were identiﬁed in the NMR spectra by comparing
their 1H chemical shifts and coupling patterns with corresponding
valuesofmetabolites frompubliclyaccessibledatabanks [12], includ-
ing the BioMagRes data bank (http://www.bmrb.wisc.edu), the
Metabolomics Database of Linkoping (http://www.mdl.imv.liu.se),
and the Human Metabolome Data Bank (http://www.hmdb.ca).
2.10. Statistical and multivariate analysis
All experiments in this study were performed in triplicate to
test the reproducibility of the results. Quantitative data were
expressed as the mean ± S.D. Statistical analysis was performed
by two-tailed Student’s t-test. Relationships were considered
statistically signiﬁcant with P < 0.05. Unsupervised principal com-
ponent analysis (PCA) was used to obtain a general overview of the
variance of the metabolites, and supervised orthogonal projection
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to obtain information about differences in the metabolite composi-
tion of samples in SIMCA-P+ (Version 12.0, Umetrics, Umeå, Swe-
den). The map of the metabolic pathways was obtained from the
Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.ge-
nome.jp/kegg/), a publicly available, web-based tool.
3. Results
3.1. Knockdown of ARNT2 mRNA expression in MCF7 cells
This study focused on the potential function of ARNT2 in human
breast cancer cells. First, we sought to downregulate the mRNA
expression of ARNT2 in MCF7 cells using siRNA techniques, the ef-
fects of which were conﬁrmed by gene expression analysis and a
cell viability assay. As shown in Fig. 1A, siARNT2 treatment caused
a dose-dependent downregulation of ARNT2 mRNA expression.
When treated with 10 and 100 nM siARNT2 for 72 h, we observed
nearly 40% and 60% reductions, respectively, in ARNT2 mRNA
expression in MCF7 cells. No signiﬁcant effect was observed in
ARNT mRNA expression with siARNT2 treatment (Fig. 1A). Further-
more, according to the cell viability assay, a signiﬁcant inhibition in
cell growth (approximately 80%) was observed in MCF7 cells trea-
ted with 100 nM, but not 10 nM, siARNT2 for 72 h (Fig. 1B). Hoe-
chst staining indicated that a high dose of siARNT2 treatment at
100 nM induced apoptosis in MCF7 cells (data not shown).
To avoid cytotoxicity, 10 nM siARNT2 was used in subsequent
experiments to investigate the effects of ARNT2 mRNA downregu-
lation on HIF-1-regulated signaling and metabolism in MCF7 cells.A
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Fig. 1. siRNA-mediated downregulation of ARNT2 mRNA expression in MCF7 cells.
Cells were treated with 10 and 100 nM siARNT2 for 72 h and then cultured for
another 48 h in steroid-free media without siARNT2 treatment. Dose-dependent
decreases in ARNT2 mRNA expression (A) and cell viability (B) following the
siARNT2 treatment were conﬁrmed. No signiﬁcant effect was observed in ARNT
mRNA expression with siARNT2 treatment (A). ⁄P < 0.05 vs. the control cells treated
with scramble siRNA.3.2. Effects of ARNT2 mRNA downregulation in the expression of HIF
signaling genes
A human HIF-regulated cDNA plate assay was used to measure
the expression of HIF-1-regulated genes. The plate comprised a to-
tal of 21 genes involved in HIF-1 signaling. As shown in Fig. 2,
downregulation of ARNT2 mRNA expression by 10 nM siARNT2
treatment for 72 h led to a 3.36-fold induction of sensitive to apop-
tosis gene (SAG) expression, and a 2-fold induction of Leptin
expression. Furthermore, we observed a 0.27-fold and 0.35-fold
reduction in von Hippel-Lindau (VHL) and matrix metalloprotein-
ase-1 (MMP1) gene expression, respectively, as well as 0.5-fold
reductions in glucose transporter 1 (Glut-1), Glut-3 and HIF-1a
genes. These results indicated that ARNT2 may be involved in the
modulation of HIF-1 signaling in MCF7 cells.
3.3. Metabolite proﬁling of MCF7 cells by 1H NMR
A representative 1D 1H NMR spectra of MCF7 cells without any
treatment is shown (Fig. 3). Most of the information is located in
the upﬁeld region between 0.7 and 4.7 ppm (Fig. 3A), which corre-
sponds to low molecular weight endogenous metabolites. The ma-
jor metabolite classes observed included amino acids (e.g., alanine,
valine, and tyrosine), organic osmolytes (e.g., betaine and glycine),
organic acids (e.g., acetic acid), carbohydrates (e.g., glucose), nucle-
otides (e.g., ATP), and glycolytic products (e.g., lactate and
pyruvate).
3.4. Effects of downregulation of ARNT2 mRNA expression in the
metabolism of MCF7 cells
To determine which metabolites signiﬁcantly correlated with
the downregulation of ARNT2 mRNA expression, PCA and OPLS-
DA modelings were applied to the 1H NMR spectra of six indepen-
dent data sets from control cells and cells with siARNT2 treatment
(n = 3, respectively). PCA is a standard technique of pattern recog-
nition and multivariate data analysis. The scores plot (PC 1 vs. 2)
discriminated between the intracellular metabolites of control
cells and cells treated with siARNT2 (Fig. 4A). It should be noted
that these differences were identiﬁed using an unsupervised anal-
ysis, without any prior information about the samples. Since allR
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Fig. 2. Effects of downregulation of ARNT2 mRNA expression in the expression of
HIF signaling genes in MCF7 cells. Cells were treated with 10 nM siARNT2 for 72 h
and then cultured for another 48 h in steroid-free media without siARNT2
treatment. The expression of HIF signaling genes was then measured using a
human HIF-regulated cDNA plate assay (Signosis). Relative mRNA expression
normalized to beta-actin was shown as log2 ratio, with the fold-change referring to
the control cells. ⁄P < 0.05, ⁄⁄P < 0.01 vs. the control cells treated with scramble
siRNA.
Fig. 3. Assignment of 1D NMR spectra of MCF7 cells. (A) Expansion of the 1H NMR spectrum from 0.7 to 4.7 ppm. (B) Expansion of the 1H NMR spectrum from 5.4 to 9.6 ppm.
Metabolites: 1, isoleucine; 2, leucine; 3, valine; 4, lactic acid (lactate); 5, threonine; 6, alanine; 7, acetic acid (acetate); 8, glutamate; 9, glutamine; 10, pyruvic acid (pyruvate);
11, phosphocholine; 12, glycerophosphocholine; 13, betaine; 14, glucose; 15, ATP/ADP/AMP; 16, tyrosine; 17, glycine; 18, NAD+/NADP+; 19, 4-nitrophenol; 20,
phenylalanine.
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crimination demonstrates that the downregulation of ARNT2
mRNA expression is strongly represented by the individual meta-
bolic proﬁles.
In contrast to PCA, OPLS-DA is a supervised method that
explains maximum separation between pre-deﬁned classes in the
data. In this case, the scores plot separated control cells and cells
treated with siARNT2 along the discriminating t[1] (data not
shown). Potential biomarkers for the separation were subsequently
identiﬁed using S-plot, which were represented with covariance
(p) against correlation (pcorr). The S-plot of the OPLS-DA showed
the most relevant variables in the differentiation of two samples,
and the identiﬁed biomarkers are highlighted in Fig. 4B. The levels
of betaine, glucose, glycine, phosphocholine, pyruvate, lactate and
ATP/ADP/AMP were signiﬁcantly decreased in cells with siARNT2
treatment, indicating that the downregulation of ARNT2 mRNA
expression may impair HIF-1-regulated glycine synthesis and glu-
cose metabolism in MCF7 cells.
4. Discussion
ARNT2 function is hypothesized to be related to organ develop-
ment, since Arnt2 knockout mice and zebraﬁsh suffer severe devel-
opmental defects and die shortly after birth [18,19]. Compared to
its homolog ARNT, ARNT2 is reported to have a more restricted
pattern of expression, commonly found in the central nervous sys-
tem and other developing organs, such as the kidney [4]. However,
recent studies have found a increased frequency of ARNT2 tran-
scripts in tumor specimens from primary breast cancer patients,
as compared with normal breast tissue samples. Moreover, the
mRNA expression levels of ARNT2 correlate signiﬁcantly with
favorable disease outcomes for breast cancer patients, suggesting
ARNT2 might be associated with cancer development, treatmentand outcome [5]. In this study, we sought to investigate the poten-
tial function of ARNT2 in HIF-1-regulated signaling and metabo-
lism in breast cancer, using siRNA to knockdown ARNT2 mRNA
expression in MCF7 cells.
HIF-1 regulates numerous pathways that are potentially impor-
tant for tumor growth, including angiogenesis and glycolysis [20].
Whilst much attention has focused on its role in the cellular
response to hypoxia, HIF-1 is also constitutively expressed in many
tumors [21]. HIF-1 is a heterodimeric transcription factor com-
posed of HIF-1a, which dimerizes with a constitutively expressed
b-subunit, such as ARNT and ARNT2, and subsequently binds to
hypoxia response elements in the promoters of target genes
[4,8]. HIF-1a expression in cells is known to be regulated by a vari-
ety of stimuli, including ﬂuctuations in cellular oxygen concentra-
tion, growth factors, oncogenic activation, or loss of tumor
suppressor function [22]. In this study, knockdown of ARNT2
mRNA expression signiﬁcantly decreased HIF-1a expression
(0.58-fold, P = 0.049), while no signiﬁcant effect was found with
HIF-2a expression (1.25-fold, P = 0.60). Although HIF-1a and HIF-
2a share similar protein structure and are both key transcriptional
regulators of the hypoxic response, several physiological and
mechanistic differences between HIF-1a and HIF-2a have been
reported [23]. A recent study found a switch in HIF-1a- to HIF-
2a-dependent signaling in cancer cells, and that overexpression
of the E3-ubiquitin ligase, hypoxia-associated factor, could
decrease HIF-1a levels but not HIF-2a in normoxic or hypoxic con-
ditions [24]. Our ﬁndings suggest that ARNT2 might be a potential
mediator of HIF-1, but not HIF-2, signaling pathways in MCF7 cells;
however, the precise mechanism of action remains to be
determined.
We observed signiﬁcant changes to the expressions of several
other proteins in response to ARNT2 knockdown, including an
increase in SAG expression, and decreases in VHL and MMP1
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tion of VHL has been implicated in the pathogenesis of several can-
cers [25]. The cellular levels of HIF-1a are tightly regulated via
post-translation modiﬁcation by prolyl hydroxylases and the
VHL, Cullin and Elongin B/C E3-ubiquitin ligase [26]. Furthermore,
in renal carcinoma cells, VHL has been shown to negatively regu-
late HIF-1a and other hypoxia-inducible genes [25,27]. When
VHL expression is lost in renal cancers, HIF-1a is constitutively sta-
ble (even in normoxia), resulting in constitutive transcription of its
target genes and the loss of VHL-mediated tumor suppression. In
our study, the knockdown of ARNT2 mRNA expression inhibited
VHL expression, which, in turn, activated HIF-1a signaling.
We observed an increase in SAG expression in response to
ARNT2 knockdown in MCF7 cells. SAG encodes a redox-inducible
and apoptosis-protective antioxidant protein that, when over-
expressed, protects mammalian cells from hypoxia-induced
apoptosis [26]. A HIF-1-SAG feedback loop has been reported pre-
viously, where the inactivation of VHL induces HIF-1 to transacti-
vate SAG, which, in turn, mediates the ubiquitination and
degradation of HIF-1a [26]. This feedback loop is in accordance
with our observations. In addition, the inhibition of HIF-1a may
have caused the decrease in MMP1 that we observed, and poten-
tially other hypoxia-inducible genes [28,29]. It should be noted
that the knockdown of ARNT2 expression showed differential
effects on the transcriptions of HIF-target genes (as shown inFig. 2). Although several factors involved in the regulation of gene
expression might contribute to this, including differences in the
promoter structure and binding afﬁnity, further study is warranted
to ascertain the underlying mechanism of action.
Numerous reports have alluded to the shift in glucose metabo-
lism that occurs in cancer cells: from oxidative to glycolytic path-
ways, in the presence of oxygen [7]. This process is known as the
Warburg effect, where HIF-1a-dependent transcriptional regula-
tion of virtually all of the genes in the glycolytic pathways lies at
the center of this effect, including the regulation of glucose trans-
porters, glycolytic enzymes, proteins involved in lactate produc-
tion and others involved in pyruvate metabolism [8]. Our gene
expression analysis found that the downregulation of ARNT2
mRNA expression in MCF7 cells signiﬁcantly inhibited the expres-
sion of Glut-3: a predominant glucose transporter responsible for
glucose uptake in neurons and cancer cells. This ﬁnding indicates
that ARNT2 may regulate HIF-1-mediated glucose and energy
metabolism [29]. Our metabolite analysis lends further support
to this hypothesis, with signiﬁcant decreases in glycine, an essen-
tial precursor of ATP synthesis, as well as other intermediates re-
lated to glycine synthesis (phosphocholine and betaine) in cells
treated with siARNT2. Moreover, the breakdown products of pyru-
vate and lactate were also decreased following siARNT2 treatment.
Our results suggest that the knockdown of ARNT2 mRNA expres-
sion may disrupt HIF-1-regulated glucose and energy metabolism
X.-Y. Qin et al. / FEBS Letters 585 (2011) 3310–3315 3315by inhibiting the expression of hypoxia-inducible genes, such as
Glut-3 (Fig. 4C). These observations are in agreement with previous
studies, suggesting that disruption of the HIF-1 pathway in tumor
cells could impair the supply of anabolic precursors required for
cell synthesis [7,21].
In our previous study, we showed that xenoestrogens, such as
bisphenol A (BPA), can downregulate ARNT2 mRNA and protein
expressions in MCF7 cells [15]. Combined with these new ﬁndings,
it is plausible to suggest that prenatal and/or long-term chronic
exposure to xenoestrogens could affect human fetal health by
impairing ARNT2 function, without any signiﬁcant symptoms, until
the accumulated effects possibly lead to tumorigenesis in later life.
This may be of particular importance because humans are still
widely exposed to xenoestrogens. For example, BPA is still produced
worldwide and employed in the manufacture of commonly used
polycarbonate plastic products and personal care products [30].
ARNT2 is involved in numerous other physiological pathways,
such as in AHR signaling, which is important in the metabolic acti-
vation and detoxiﬁcation of ubiquitous environmental pollutants
and carcinogens, including dioxins and benzo[a]pyrenes (BaP)
[1–3]. Interestingly, a recent study reported a two-way interaction
between HIF-1 and AHR pathways, where HIF-1a activation signif-
icantly reduced the levels of AHR downstream targets genes and
increased BaP-induced genetic instability [31]. Our results suggest
that ARNT2 may play a role in cancer development by a HIF-1-
mediated mechanism that perhaps also includes the modulation
of AHR signaling and carcinogen metabolism. However, the details
of this mechanism of action are still unclear, and further experi-
mentation is warranted.
5. Conclusions
In summary, we described a role for ARNT2 in the modulation of
HIF-1-regulated signaling and metabolism in MCF7 cells. ARNT2 is
an essential regulator involved in the physiological response to
several critical environmental insults, including chemical toxins
and hypoxia. The regulatory effects of ARNT2 on the tumor sup-
pressor activity of VHL and the anti-apoptosis activity of SAG sug-
gest the potential role of ARNT2 in cancer development, treatment
and outcome. However, a detailed mechanism of action is still un-
clear from this limited study, and further research to elucidate the
functions of ARNT2 in more detail is necessary in epidemiology
studies and in different in vivo and in vitro models.
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